Evidence map›Paper›PMID 35505417›Full record

ArticleJournal of hematology & oncology2022

Prostate cancer multiparametric magnetic resonance imaging visibility is a tumor-intrinsic phenomena.

Amanda Khoo, Lydia Y Liu, Taylor Y Sadun, Amirali Salmasi, Aydin Pooli, Ely Felker, Kathleen E Houlahan, Vladimir Ignatchenko, Steven S Raman, Anthony E Sisk and 3 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hematology & oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Should systematic prostatic biopsies be discontinued?Prostate cancer and prostatic diseases · 2025
    Review
  5. Article
  6. The Proteogenomics of Prostate Cancer Radioresistance.Cancer research communications · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Amanda KhooDepartment of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Lydia Y LiuDepartment of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Taylor Y SadunDepartment of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Amirali SalmasiDepartment of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Aydin PooliDepartment of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Ely FelkerDepartment of Radiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Kathleen E HoulahanDepartment of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Vladimir IgnatchenkoPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Steven S RamanDepartment of Radiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Anthony E SiskDepartment of Pathology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Robert E ReiterJonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. rreiter@mednet.ucla.edu.
Paul C BoutrosDepartment of Medical Biophysics, University of Toronto, Toronto, ON, Canada. PBoutros@mednet.ucla.edu.
Thomas KislingerDepartment of Medical Biophysics, University of Toronto, Toronto, ON, Canada. thomas.kislinger@mail.utoronto.ca.ORCID 0000-0003-3525-5540

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Development of Protein Biomarkers in Post-DRE Urine for use in Liquid Biopsy of Prostate CancerU01CA214194 · NCI · EASTERN VIRGINIA MEDICAL SCHOOL · PI BOUTROS, PAUL CHRISTOPHER, KISLINGER, THOMAS · 2016 to 2021
$2.5M
Canadian Cancer Society 705649CIHR 388344CIHR PJT162384Foundation for the National Institutes of Health 1U01CA214194-01NCI NIH HHS P30 CA016042NCI NIH HHS U01 CA214194Prostate Cancer Foundation 20CHAS01
6 · The paper itself

Abstract

Multiparametric magnetic resonance imaging (mpMRI) is an emerging standard for diagnosing and prognosing prostate cancer, but ~ 20% of clinically significant tumors are invisible to mpMRI, as defined by the Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) score of one or two. To understand the biological underpinnings of tumor visibility on mpMRI, we examined the proteomes of forty clinically significant tumors (i.e., International Society of Urological Pathology (ISUP) Grade Group 2)-twenty mpMRI-visible and twenty mpMRI-invisible, with matched histologically normal prostate. Normal prostate tissue was indistinguishable between patients with visible and invisible tumors, and invisible tumors closely resembled the normal prostate. These data indicate that mpMRI-visibility arises when tumor evolution leads to large-magnitude proteomic divergences from histologically normal prostate.

Indexed as

Multiparametric Magnetic Resonance ImagingProstatic NeoplasmsHumansMaleNeoplasm GradingProstateProteomicsMultiparametric magnetic resonance imagingProstate cancerProteomics

Identifiers

PMID35505417
PMCPMC9066728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.